Oct-06-03 09:39am From-SIMBAS

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**Applicant** 

Robert C. Brunham

Appl'n. No.

09/857,305

Filed

October 3, 2001

Title

TWO-STEP IMMUNIZATION PROCEDURE AGAINST

CHLAMYDIA INFECTION

Grp./A.U.

1645

Examiner

Khatol S. Shahnan-Shah

Docket No.

1038-1153 MIS:jb

Date

October 6, 2003

RECEIVED

Via Facsimile

(703) 305-3014

OCT 0.8 2003

Mail Stop Amendment Commissioner of Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 U.S.A. TECH CENTER 1600/2900

## AMENDMENT

Dear Sir:

This Commission is submitted in respect to the Office Action of September 5, 2003.

The Examiner required an election of a single invention among three groups of claims. The applicants hereby elect the claim of Group II, namely claims 19 to 28, drawn to an attenuated bacterium. This election is made without prejudice to applicants right to file one or more divisional or continuation applications directed to the non-elected invention.

The election is made with traverse. The Examiner indicates that

"The special technical feature testing Groups I to III appears to be immunological activity of a major outer membrane protein (MOMP) of a strain of *Chlamydia*. However, Agabian et al teach immunological activity of the major outer membrane protein (MOMP) of a strair of *Chlamydia*.

Application No.: 09/857,305

2

"Therefore, the technical feature listing the invention of Groups I to II does not constitute a special technical feature as defined by PCT Rules 13.2, as it doe not define a contribution over the prior art."

It is submitted that the Examiner is incorrect. It is true that Agabian et al disclose that MOMP is immunogenic. However, the reference shows only that *in vitro* recombinantly produced MOMP protein is immunogenic.

Applicants claims all involve the use of an attenuated bacteria harbouring a nucleic acid molecule encoding at least one immunoprotection-inducing *Chlamydia* protein or fragment thereof which generates a *Chlamydia* protein specific immune response, specifically MOMP. Claims 1 to 18 are directed to a two ster immunization procedure and claims 29 to 40 are directed to one step immunization procedure using said attenuated bacteria while claims 19 to 28 are directed to bacteria itself.

The special feature linking the groups of the claims, therefore, is the attenuated bacteria and its use in DNA immunization. As is clear from the disclosure on page 8, lines 7 to 15, the transfected DNA (i.e. the nucleic acid molecule encoding MOMP) is not expressed in the bacterial vector and hence the attenuated bacterium could not be used to produce *in vitro* MOMP, as in Agabian et al. The expression of the DNA is effected when the bacterial vector has released the LINA into the appropriate host cells. After uptake of the bacterial vector by the host cells, the auxotrophic bacteria dies after a few rounds of division and the plasmid DNA then is released into the cytoplasm of the infected host cells and the encoded gene expressed in the host cell.

Accordingly, it is submitted that the restriction requirement is improper and that all claims should be examined in this application. Nevertheless, as noted above, applicants have elected the claims of Group II.

In addition, the Examiner required an election of species, indicating that, with respect to the claims of Group II, an election was required between the

Application No.: 09/857,305

3

Chlamydia species of claims 21 and 22. The applicants hereby elect the species of claim 22, namely C. trachomatis. Claims 19, 20 and 23 to 29 are generic thereto

The species election is made without prejudice to the applicants riç ht, up-on the allowance of a generic claim, to consideration of claims to additional species which are written in dependent form or otherwise include the limitations of an allowed claim.

Respectfully submitted

Michael I. Stewart Reg. No. 24,973

RECEIVED CENTRAL FAX CENTER

OCT 0 6 2003

OFFICIAL

Toronto, Ontario, Canada (416) 595-1155 FAX No. (416) 595-1163

T-989 P.001/006 F-677

## Sim, Hughes, Ashton & McKay LLP

Barristers & Solicitors

Sim & McBurney

Patent & Trade Mark Agents

6<sup>th</sup> Floor, 330 University Avenue Toronto, Ontario, Canada M5G 1R7

Tel. (416) 595-1155 • Fax (416) 595-1163

**DATE: October 06, 2003** 

Application No.: 09/857,305

Our Ref: 1038-1153 MIS:jb

TO:	FAX#	PHONE #
USPTO Commissioner of Patents Examiner: Khatol S. Shahnan-Shah Art Unit : 1645	(703) 305-3014	(703) 308-3896

Total Number of Pages (Including This Page): 6

FROM: Michael I. Stewart / 239

COMMENTS:

RECEIVED

OCT 0 8 2003

TECH CENTER 1600/2900

RECEIVED CENTRAL FAX CENTER

OCT 0 6 2003

We are transmitting from a Xerox Telecopier 7033, 7020 or Workcentre Pro 745 – Group 3 which are compatible with Groups 1 and 2 and fully automatic on a 24 hour basis. If any part of this message is received poorly or missin; please call the telecopier operator immediately at (416) 595-1155.

## **Confidentiality Notice**

This message is intended only for the use of the individual person or entity to which it is addresses and may contain information that is privileged and confidential. If the reader of this message is not the intended recipient or the agent responsible for delivering the message to the intended recipient, you are hereby notified that any disclosing, copying, distributing or the taking of any action in rellance on the contents of this communication is prohibited. If you have received this communication in error, please notify us immediately by telephone (call collect) and return the original mestage to us at the above address via the postal service. Thank you.

				d Tredemark	d for uso through 07/31/2008. OM c Office: U.S. OEPARTMENT OF (	COMMERCE	
Under the Paperw	on, AEEE to 11A moissupp A no.	> beteoUs aux Led-suco	d to respond to a collection of In  Application Number		unioss it displays a valid OMS cor 09/857,305	r irol humber.	1
TR	ANSMITT	AL	Filing Date		October 3, 2001	REC	EIVED
	FORM	<u>-</u>	First Named Inventor		Robert C. Brunham		0.8 2003
(to be used to	for all correspondence after	r initial filling) j	Art Unit		1645		
		<del></del>	Examiner Name	<u> </u> 1	Khatol S. Shahoan-Shah	FCH CEN	TER 1600/2900
Total Number of	f Pages in This Submission	n 5	Attorney Docket Numl		1038-1153 MIS:jb		<u>/</u>
		ENCLOS	SURES (chock all that	t apply)		·	]
Fee Transmit	ittel Form	Drawing(s	(3)		After Allowance commuto Group		
Fee #	Attached	Licensint	ng-rélated Papers	<u> </u>	Appeal Communication of Appeals and Interfer	rinces	
Amendment	: / Reply	Petition		<u> </u>	Appeal Communication (Appeal Notice, Brist,		1
Afte	ter Final	Provision	to Convert a nal Application	Į	Proprietary Information	, !	
Affic	idavits/declaration(s)		of Attorney, Revocation of Correspondence	L	Status Letter	l	
Extension of	of Time Request	Terminal	l Disclaimer	D	Other Enclosure(s) (£ identify below):	'ease	
Express Ape	andonment Request	Request	t for Refund		Certificate of Trapsn i Pacsimile	ission by	
Information (	Disclosure Statement	CD, Nun	mber of CD(s)		1	CEIVED	
Certified Cop Document(s)	opy of Priority (5)	Remarks	T	<u> </u>	1	AL FAX CEN	
Response to	to Missing Parts/ Application		1		OCT	T 0 6 200	3
Resp	sponse to Missing Parts der 37 CFR 1.52 or 1.53				.a. a. a.	! ~ n	l <sub>n</sub>
	<u></u>						
<u> </u>	SIGNATUR	RE OF APPLICA	ANT, ATTORNEY, OR A	GENT	W V U	עוט 🏈 וו	
Firm or Individual name	Michael I. Stewart (Reg. No. 24,973)						
Signature	Michael 1.	1. 8Jena	nt.				
Date							
	CE	PTIFICATE OF	F TRANSMISSION/M	MAILING	2		, <b>L</b>
I nereby certify that to sufficient postage as	this correspondence is bein	ing facsimile transmi	nitted to the USPTO or depo	posited with	h the United States Postal : ie x 1450, Alexandria,VA 223 3	ervice with 3-1450 on the	
Typed or printed nan	ame						1
Signature				Date			1

This collection of Information is required by 37 CFR 1.5. The Information is required to bit or retain a benefit by the public wi ich is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including sathering, preparing, and submitting the completed application form to the USPTO. Time will van depending upon the Individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this turden, should be sent to the Chief Information Officer. U.S. Patent and Trademark Office. U.S. Department of Commerce, P.O. Box 1450 Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissionar for Patents P.O. Box 1450, Alexandria, VA 22313-1450.

CERTIFICATE OF TApplicant(s): Robert C. E	CSIMILE (37 CFR 1.8)	Docket No. 1038-1153 MIS:jb		
Serial No. 09/857,305	Filing Date October 3, 2001	Examiner Khatol S. Shahnan-Shah	Grc up Art Unit 1645	
nvention: TWO-STEP I	MMUNIZATION PROCEDU	RE AGAINST CHLAMYDIA INFE	CTION	
		Amendment		
hereby certify that this	itted to the United States Pate	(Identify type of correspondence) ant and Trademark Office (Fax. No.	(703) 305-3 014	
s being facsimile transmi on October 6,		The free free free (1 and 1)		
(Date)				
		·		
		Michael I. Stewart (Reg. (Typed or Printed Name of Person S	No. 24,973) Signing Certifics (e)	
		Michael 1. (Signature)	Steward	
			TIVED	
			RECEIVED	
			OCT 0.8 2003	
	Note: Each paper must	have its own certificate of mailing.	TECH CENTER 1600	
	•		JEON	
•				